<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00443846</url>
  </required_header>
  <id_info>
    <org_study_id>V260-016</org_study_id>
    <secondary_id>S06-ROT-304</secondary_id>
    <secondary_id>2006-005445-11</secondary_id>
    <nct_id>NCT00443846</nct_id>
  </id_info>
  <brief_title>RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)</brief_title>
  <official_title>An Open-label, Randomised, Comparative, Multi-centre Study of the Immunogenicity and Safety of the Concomitant Use of a Live Pentavalent Rotavirus Vaccine (RotaTeq®) and a Meningococcal Group C Conjugate (MCC) Vaccine in Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      To check if RotaTeq® can be administered concomitantly with meningococcal Group C vaccine
      without impairing the efficacy of MCC vaccine. The hypothesis tested is that the
      seroprotection rate for MMC at 28 days after the second MCC vaccination with concomitant
      administration of RotaTeq® is non-inferior to that without non-concomitant (sequential)
      administration of RotaTeq®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2007</start_date>
  <completion_date type="Actual">October 23, 2007</completion_date>
  <primary_completion_date type="Actual">September 4, 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Seroresponse for Meningiococcal Group C Serotype</measure>
    <time_frame>28 days after the second dose of MCC vaccine (approximately 20 weeks)</time_frame>
    <description>Antibody seroprotection to meningiococcal Group C serotype was measured by serum bactericidal antibody with rabbit complement (sRBA). The criterion for seroresponse was an sRBA titer &gt;=1:8.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">247</enrollment>
  <condition>Meningitis, Meningococcal</condition>
  <condition>Rotavirus Infections</condition>
  <arm_group>
    <arm_group_label>Group 1: Concomitant Administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 2 concomitant doses of RotaTeq® and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age and a third dose of RotaTeq® at 24-25 weeks of age (and 28 to 42 days after the vaccine administration at 20-21 weeks of age).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Sequential Administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 3 doses of RotaTeq® at 6-7 weeks of age, 15-16 weeks of age, and 24-25 weeks of age (and 28 to 42 days after the MMC vaccine administered at 20-21 weeks of age), and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RotaTeq®</intervention_name>
    <description>Rotavirus vaccine, live, oral, pentavalent, 2 mL solution for oral administration.</description>
    <arm_group_label>Group 1: Concomitant Administration</arm_group_label>
    <arm_group_label>Group 2: Sequential Administration</arm_group_label>
    <other_name>V260</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NeisVac-C®</intervention_name>
    <description>Meningiococcal Group C Polysaccharide Conjugate Vaccine Absorbed, 0.5 mL suspension for intramuscular injection.</description>
    <arm_group_label>Group 1: Concomitant Administration</arm_group_label>
    <arm_group_label>Group 2: Sequential Administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infants, aged from 6 weeks through full 7 weeks,

          -  Consent form signed by at least one parent or by the legal representative properly
             informed about the study,

          -  Parent(s) / legal representative able to understand the protocol requirements and to
             fill in the Diary Card.

        Exclusion Criteria:

          -  History of congenital abdominal disorders, congenital malformation of the
             gastrointestinal tract that could predispose to intussusception, or abdominal surgery,

          -  Congenital fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase
             insufficiency,

          -  Known or suspected impairment of immunological function,

          -  Known hypersensitivity to any component of RotaTeq® (e.g. sucrose) or of NeisVac-C®
             (including tetanus toxoid),

          -  Prior administration of any rotavirus vaccine,

          -  Prior administration of any vaccine within the 28 days prior to randomisation,

          -  Fever (rectal temperature ≥38.1°C) and/or acute diarrhoea and/or vomiting at
             randomisation,

          -  History of known prior rotavirus gastroenteritis, chronic diarrhoea, or failure to
             thrive,

          -  Any severe thrombocytopenia or any other coagulation disorder that would
             contraindicate intramuscular injection,

          -  Clinical evidence of active gastrointestinal illness,

          -  Receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 14
             days prior to randomisation. Note: Infants on inhaled and/or topical steroids may
             participate in the study,

          -  Infants residing in a household with an immunocompromised person,

          -  Prior receipt of a blood transfusion or blood products, including immunoglobulins.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>55 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Finland</country>
  </removed_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>March 5, 2007</study_first_submitted>
  <study_first_submitted_qc>March 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2007</study_first_posted>
  <results_first_submitted>September 8, 2017</results_first_submitted>
  <results_first_submitted_qc>September 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 20, 2018</results_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention of Gastroenteritis due to rotavirus infection. And prevention of Invasive disease caused by Neisseria meningitidis serogroup C.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis, Meningococcal</mesh_term>
    <mesh_term>Rotavirus Infections</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 249 participants were screened and 247 were randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Concomitant Administration</title>
          <description>Participants received 2 concomitant doses of RotaTeq® and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age and a third dose of RotaTeq® at 24-25 weeks of age (and 28 to 42 days after the vaccine administration at 20-21 weeks of age)</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Sequential Administration</title>
          <description>Participants received 3 doses of RotaTeq® at 6-7 weeks of age, 15-16 weeks of age, and 24-25 weeks of age (and 28 to 42 days after the MMC vaccine administered at 20-21 weeks of age), and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawn due to intercurrent disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not vaccinated, no blood sample drawn</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal reason</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Concomitant Administration</title>
          <description>Participants received 2 concomitant doses of RotaTeq® and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age and a third dose of RotaTeq® at 24-25 weeks of age (and 28 to 42 days after the vaccine administration at 20-21 weeks of age)</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Sequential Administration</title>
          <description>Participants received 3 doses of RotaTeq® at 6-7 weeks of age, 15-16 weeks of age, and 24-25 weeks of age (and 28 to 42 days after the MMC vaccine administered at 20-21 weeks of age), and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
            <count group_id="B2" value="123"/>
            <count group_id="B3" value="247"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.1" spread="0.5"/>
                    <measurement group_id="B2" value="7.2" spread="0.6"/>
                    <measurement group_id="B3" value="7.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Seroresponse for Meningiococcal Group C Serotype</title>
        <description>Antibody seroprotection to meningiococcal Group C serotype was measured by serum bactericidal antibody with rabbit complement (sRBA). The criterion for seroresponse was an sRBA titer &gt;=1:8.</description>
        <time_frame>28 days after the second dose of MCC vaccine (approximately 20 weeks)</time_frame>
        <population>The population analyzed was randomized participants excluding those with protocol violations that may have interfered with the immunogenicity evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Concomitant Administration</title>
            <description>Participants received 2 concomitant doses of RotaTeq® and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age and a third dose of RotaTeq® at 24-25 weeks of age (and 28 to 42 days after the vaccine administration at 20-21 weeks of age)</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Sequential Administration</title>
            <description>Participants received 3 doses of RotaTeq® at 6-7 weeks of age, 15-16 weeks of age, and 24-25 weeks of age (and 28 to 42 days after the MMC vaccine administered at 20-21 weeks of age), and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Seroresponse for Meningiococcal Group C Serotype</title>
          <description>Antibody seroprotection to meningiococcal Group C serotype was measured by serum bactericidal antibody with rabbit complement (sRBA). The criterion for seroresponse was an sRBA titer &gt;=1:8.</description>
          <population>The population analyzed was randomized participants excluding those with protocol violations that may have interfered with the immunogenicity evaluation.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="96.5" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="96.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of non-inferiority was based on the Miettinen and Nurminen method</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was concluded if the lower bound of the 95% confidence interval of the difference (Group 1 - Group 2) in seroprotection rate was greater than -10%.</non_inferiority_desc>
            <param_type>Difference (Group 1 - Group 2)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>3.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious and other adverse events: up to 13 days after any vaccination visit; solicited diarrhea, vomiting, and temperature: up to 6 days after any vaccination visit; deaths and vaccine- or procedure-related serious adverse events: up to 27 weeks.</time_frame>
      <desc>The population at risk was all vaccinated participants. One participant in Group 2 was excluded because they were lost to follow-up after receiving only the first dose of RotaTeq®.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Concomitant Administration</title>
          <description>Participants received 2 concomitant doses of RotaTeq® and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age and a third dose of RotaTeq® at 24-25 weeks of age (and 28 to 42 days after the vaccine administration at 20-21 weeks of age)</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Sequential Administration</title>
          <description>Participants received 3 doses of RotaTeq® at 6-7 weeks of age, 15-16 weeks of age, and 24-25 weeks of age (and 28 to 42 days after the MMC vaccine administered at 20-21 weeks of age), and MCC vaccine at 10-11 weeks of age and 20-21 weeks of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="116"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="116"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="116"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="52" subjects_affected="38" subjects_at_risk="116"/>
                <counts group_id="E2" events="73" subjects_affected="48" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="116"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Regurgitation of food</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="116"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="36" subjects_affected="30" subjects_at_risk="116"/>
                <counts group_id="E2" events="40" subjects_affected="27" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection-site erythema</sub_title>
                <counts group_id="E1" events="30" subjects_affected="26" subjects_at_risk="116"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Injection-site induration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Injection-site pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="116"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Injection-site swelling</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="76" subjects_affected="59" subjects_at_risk="116"/>
                <counts group_id="E2" events="79" subjects_affected="51" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="38" subjects_affected="32" subjects_at_risk="116"/>
                <counts group_id="E2" events="36" subjects_affected="34" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="116"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="116"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="116"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="116"/>
                <counts group_id="E2" events="31" subjects_affected="25" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="116"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="116"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

